INmune Bio (NASDAQ:INMB) Coverage Initiated by Analysts at Raymond James

Raymond James assumed coverage on shares of INmune Bio (NASDAQ:INMB) in a research note released on Friday, Marketbeat.com reports. The firm issued an outperform rating and a $18.00 price objective on the stock.

Separately, Scotiabank assumed coverage on INmune Bio in a research report on Thursday, August 22nd. They set a sector outperform rating and a $22.00 price objective for the company.

INmune Bio Stock Up 5.2 %

NASDAQ:INMB opened at $5.22 on Friday. INmune Bio has a 1-year low of $4.81 and a 1-year high of $14.74. The firm has a market capitalization of $103.26 million, a price-to-earnings ratio of -2.72 and a beta of 1.86. The stock has a fifty day simple moving average of $6.79 and a 200 day simple moving average of $8.83.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%.

Insider Transactions at INmune Bio

In other news, CEO Raymond Joseph Tesi purchased 15,380 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was bought at an average cost of $6.38 per share, with a total value of $98,124.40. Following the purchase, the chief executive officer now directly owns 1,554,106 shares of the company’s stock, valued at $9,915,196.28. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CFO David J. Moss purchased 7,690 shares of the stock in a transaction on Thursday, September 12th. The shares were purchased at an average cost of $6.38 per share, for a total transaction of $49,062.20. Following the completion of the transaction, the chief financial officer now directly owns 1,275,869 shares of the company’s stock, valued at approximately $8,140,044.22. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Raymond Joseph Tesi bought 15,380 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were acquired at an average price of $6.38 per share, for a total transaction of $98,124.40. Following the acquisition, the chief executive officer now directly owns 1,554,106 shares of the company’s stock, valued at approximately $9,915,196.28. The disclosure for this purchase can be found here. Company insiders own 35.20% of the company’s stock.

Institutional Trading of INmune Bio

Large investors have recently made changes to their positions in the business. Fermata Advisors LLC grew its holdings in shares of INmune Bio by 8.5% during the second quarter. Fermata Advisors LLC now owns 34,140 shares of the company’s stock worth $301,000 after purchasing an additional 2,689 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of INmune Bio by 124.6% during the second quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after purchasing an additional 32,511 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of INmune Bio by 332.1% during the second quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after purchasing an additional 89,091 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of INmune Bio during the second quarter valued at $121,000. Finally, CVI Holdings LLC acquired a new position in shares of INmune Bio during the second quarter valued at $5,260,000. Institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.